These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36756142)

  • 41. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
    Inoue K; Masuda N; Iwata H; Takahashi M; Ito Y; Miyoshi Y; Nakayama T; Mukai H; van der Walt JS; Mori J; Sakaguchi S; Kawaguchi T; Tanizawa Y; Llombart-Cussac A; Sledge GW; Toi M
    Breast Cancer; 2021 Sep; 28(5):1038-1050. PubMed ID: 33797023
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
    Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting.
    Abdel-Razeq H; Sharaf B
    Drug Des Devel Ther; 2022; 16():727-735. PubMed ID: 35321498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.
    Patterson-Lomba O; Dalal AA; Ayyagari R; Liu O; Dervishi E; Platt E; Chandiwana D; O'Shaughnessy JA
    Breast J; 2019 Sep; 25(5):880-888. PubMed ID: 31290203
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
    J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2-early breast cancer in China.
    Wei Q; Xu Y; Liu W; Guan X
    Cost Eff Resour Alloc; 2023 Nov; 21(1):91. PubMed ID: 38012661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
    Tolaney SM; Beeram M; Beck JT; Conlin A; Dees EC; Puhalla SL; Rexer BN; Burris HA; Jhaveri K; Helsten T; Becerra C; Kalinsky K; Moore KN; Manuel AM; Lithio A; Price GL; Chapman SC; Litchfield LM; Goetz MP
    Front Oncol; 2021; 11():810023. PubMed ID: 35223458
    [TBL] [Abstract][Full Text] [Related]  

  • 48. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
    Hamilton E; Cortes J; Ozyilkan O; Chen SC; Petrakova K; Manikhas A; Jerusalem G; Hegg R; Huober J; Chapman SC; Lu Y; Hardebeck MC; Bear MM; Johnston EL; Martin M
    Clin Breast Cancer; 2021 Jun; 21(3):181-190.e2. PubMed ID: 33148479
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis.
    Zhang Z; Zhao X; Chen J
    Front Pharmacol; 2024; 15():1438288. PubMed ID: 39329126
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer.
    Sheffield KM; Peachey JR; Method M; Grimes BR; Brown J; Saverno K; Sugihara T; Cui ZL; Lee KT
    Future Oncol; 2022 Jul; 18(21):2667-2682. PubMed ID: 35611679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
    Chan A; Moy B; Mansi J; Ejlertsen B; Holmes FA; Chia S; Iwata H; Gnant M; Loibl S; Barrios CH; Somali I; Smichkoska S; Martinez N; Alonso MG; Link JS; Mayer IA; Cold S; Murillo SM; Senecal F; Inoue K; Ruiz-Borrego M; Hui R; Denduluri N; Patt D; Rugo HS; Johnston SRD; Bryce R; Zhang B; Xu F; Wong A; Martin M;
    Clin Breast Cancer; 2021 Feb; 21(1):80-91.e7. PubMed ID: 33183970
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
    Regan MM; Francis PA; Pagani O; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Price KN; Coates AS; Goldhirsch A; Gelber RD
    J Clin Oncol; 2016 Jul; 34(19):2221-31. PubMed ID: 27044936
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discrepancies in estradiol levels in a premenopausal woman receiving abemaciclib despite ovarian function suppression and bilateral salpingo-oophorectomy.
    Kessler AJ; Patel R; Gallagher EJ; Shao T; Fasano J
    Curr Probl Cancer Case Rep; 2023 Mar; 9():. PubMed ID: 37124155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
    Nitz UA; Gluz O; Kümmel S; Christgen M; Braun M; Aktas B; Lüdtke-Heckenkamp K; Forstbauer H; Grischke EM; Schumacher C; Darsow M; Krauss K; Nuding B; Thill M; Potenberg J; Uleer C; Warm M; Fischer HH; Malter W; Hauptmann M; Kates RE; Gräser M; Würstlein R; Shak S; Baehner F; Kreipe HH; Harbeck N
    J Clin Oncol; 2022 Aug; 40(23):2557-2567. PubMed ID: 35404683
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
    Toi M; Inoue K; Masuda N; Iwata H; Sohn J; Hae Park I; Im SA; Chen SC; Enatsu S; Turner PK; André VAM; Hardebeck MC; Sakaguchi S; Goetz MP; Sledge GW
    Cancer Sci; 2021 Jun; 112(6):2381-2392. PubMed ID: 33686753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Endocrine Treatment Landscape for Patients with HR+ HER2- Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy - A Real-World Analysis.
    Nabieva N; Altmann F; Apel K; Baerens DT; Beha M; Belau A; Busch S; Guth D; Heinrich G; Kreiss-Sender J; Markmann S; Olbermann A; Oskay-Özcelik G; Schuback B; Steinfeld-Birg D; Quiering C; Kiss F; Kreuzeder J; Nuti P; Schilling J
    Geburtshilfe Frauenheilkd; 2023 Sep; 83(9):1127-1137. PubMed ID: 37942358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review.
    Mata DGMM; Amir Carmona C; Eisen A; Trudeau M
    Curr Oncol; 2022 Jul; 29(7):4956-4969. PubMed ID: 35877254
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting.
    D'Onofrio R; Omarini C; Toss A; Sperduti I; Piacentini F; Barbolini M; Cortesi L; Barbieri E; Pettorelli E; Chiavelli C; Dominici M; Moscetti L
    Clin Breast Cancer; 2023 Oct; 23(7):712-720.e3. PubMed ID: 37507257
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2- Advanced Breast Cancer.
    Xie N; Qin T; Ren W; Yao H; Yu Y; Hong H
    Cancer Manag Res; 2020; 12():4241-4250. PubMed ID: 32581595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.